Coffee and aging

Coffee and aging names a long-running epidemiological finding and the claim built on it: that people who habitually drink moderate amounts of coffee die at lower rates than people who do not, and that coffee therefore slows some part of human aging. The association is among the most often replicated in nutritional epidemiology. Whether coffee causes it is unresolved, because the evidence is almost entirely observational, the genetic studies designed to test causality have mostly been null, and no randomized trial has measured survival.

§The epidemiological signal

The modern literature took shape with the NIH-AARP Diet and Health Study, which followed about 400,000 American men and women aged 50 to 71 between 1995 and 2008. In age-adjusted models coffee drinkers were more likely to die. They were also more likely to smoke, and once smoking and other confounders were adjusted for, the direction reversed: men drinking two or three cups a day had a hazard ratio for death of 0.90 relative to non-drinkers, and women drinking four or five cups 0.84. Inverse associations appeared for deaths from heart disease, stroke, respiratory disease, and several other causes, but not from Cancer. Coffee intake was measured once, at baseline, and the authors wrote that their data could not determine whether the finding was causal.¹

The pattern has since been reproduced across many populations. A 2017 umbrella review in the BMJ assembled 201 meta-analyses of observational research covering 67 outcomes, plus 17 meta-analyses of interventional studies. Coffee was more often associated with benefit than harm, with the largest relative risk reduction at three to four cups a day; for all-cause mortality the pooled relative risk against non-drinkers was 0.83. Most harmful associations disappeared after adequate adjustment for smoking, and the authors called for randomized trials to establish whether any of the associations were causal.²

In the UK Biobank, among roughly half a million adults followed for about ten years, coffee drinking was again inversely associated with mortality, including at eight or more cups a day. The association was similar for instant, ground, and decaffeinated coffee and did not vary with a genetic score for how fast a person metabolizes caffeine, which led the investigators to point to constituents other than caffeine.³ That weakens caffeine-based explanations, and is also what would be expected if coffee drinking marked something about the drinker rather than acting on the drinker's biology.

Association or cause

Every mortality estimate above comes from people who chose how much coffee to drink. Coffee drinkers differ from abstainers in smoking and other habits, and people who become ill or are advised to avoid caffeine may drink less, so illness can lower coffee intake rather than coffee lowering illness. The genetic studies built to sidestep both problems have not found the mortality benefit, and the randomized trial that would settle the question has never been run.

§Genetic tests of causation

Mendelian randomization treats genetic variants that influence coffee intake as a natural experiment, because genes are fixed at conception and unaffected by later illness or habit. In a Danish study, observational data from about 95,000 people reproduced the familiar U-shaped curve, with the lowest cardiovascular and all-cause mortality at moderate intake. An allele score associated with 42 percent higher coffee intake, however, was not associated with all-cause mortality among about 112,000 Danes (hazard ratio 1.01 per allele), nor with ischaemic heart disease in analyses that added international consortia for up to about 223,000 people, while a positive-control analysis using cholesterol-lowering ApoE variants did detect the expected effect on heart disease.⁴ A 2018 review of at least fifteen such studies, covering type 2 diabetes, cardiovascular disease, Alzheimer's and Parkinson's disease, several cancers, and other outcomes, found that most gave no consistent support for a causal role of coffee or caffeine.⁵

The null results are not decisive either. The same review lists low statistical power, possible pleiotropy, and collider bias as common weaknesses, and notes that the available instruments capture different aspects of coffee and caffeine use. The variants used lie near genes such as AHR and CYP1A1/2 that govern caffeine metabolism, so a variant that raises intake may do so by changing how quickly caffeine is cleared, which complicates what the instrument measures. In many cases, the reviewers conclude, a causal role "cannot confidently be ruled out".⁵

§Randomized evidence

No randomized trial has tested coffee against survival or against a validated measure of biological aging. The DECAF trial randomized 200 coffee drinkers with persistent atrial fibrillation or flutter, after electrical cardioversion, either to keep drinking caffeinated coffee or to abstain from coffee and caffeine for six months. Recurrence was 47 percent in the coffee group and 64 percent in the abstinence group, a hazard ratio of 0.61, contradicting the long-standing assumption that coffee provokes arrhythmia.⁶ The trial was open-label, small, and confined to one condition; it says nothing directly about aging, but shows that coffee can be studied by randomization.

§Proposed mechanisms

Coffee is a complex mixture, and the mechanistic literature concentrates on caffeine, an adenosine-receptor antagonist familiar from the Nootropics literature, and on the polyphenols called chlorogenic acids. A 2024 review argues, from studies in humans and human tissue, that coffee and these components act on several of the Hallmarks of aging (genomic instability, macromolecular damage, and metabolic and proteostatic impairment), with the most robust effects on stress adaptation and inflammation and unclear effects on stem cells and regeneration, the territory of Stem cell exhaustion.⁷

The human data on inflammation are correlational. A Stanford study of older adults found that expression of inflammasome gene modules split participants into two groups, the high-expression group carrying more hypertension and arterial stiffness; among people over 85, high expression was associated with all-cause mortality. In about ninety participants, reported caffeine intake was associated with lower expression of these modules, and caffeine metabolites were more abundant in the serum of the low-inflammation group. Caffeine also suppressed interleukin-1β secretion by a human monocytic cell line in culture.⁸ The finding connects coffee to Inflammaging but rests on a small cohort and a cell line.

The animal work is more direct and less applicable. In mice, both caffeinated and decaffeinated coffee induced Autophagy in liver, muscle, and heart within one to four hours, accompanied by inhibition of mTORC1, the nutrient-sensing kinase targeted by Rapamycin; the authors noted that these are changes also induced by nutrient depletion, the state mimicked by Caloric restriction.⁹ Trigonelline, an alkaloid abundant in coffee beans, feeds into the NAD+ pool, as the NAD+ precursors sold as supplements are meant to, in worms, mice, and cultured human muscle cells, extended worm lifespan, and improved muscle strength in ageing male mice; in humans, serum trigonelline was lower in people with Sarcopenia, an association rather than an effect. Serum trigonelline did not track caffeine intake in the study's Middle Eastern cohort, where coffee drinking is low, and the work was led by Nestlé Research scientists.¹⁰

Mechanism is not benefit

Showing that coffee constituents move markers of aging biology in cultured cells, worms, or mice does not show that the same happens at drinking doses in people, or that it explains the mortality association. If decaffeinated coffee carries the same association as caffeinated coffee, caffeine-based mechanisms cannot be the whole account even if the association is causal.

§The 2024 review and its reception

The review by Cátia Lopes and Rodrigo Cunha of the University of Coimbra, published in Ageing Research Reviews in late 2024, became a widely publicized statement of the case. Its abstract describes "strikingly consistent" evidence from more than 50 studies that moderate coffee intake "attenuates all-cause mortality", calls the benefit "discrete (17 % reduction)", equates it with "an average increase in healthspan of 1.8 years", and calls for renewed attention to recommending coffee consumption throughout life.⁷ The 17 percent figure matches the pooled mortality estimate of the 2017 umbrella review.

Its language is causal although the epidemiology it summarizes is observational. It converts a reduction in mortality, a measure of survival, into a gain in Healthspan, a measure of time lived free of disease and disability, without stating in the abstract how the conversion was made. And it asks for further studies "in aged individuals" to establish the mechanistic benefits it reports. The press release announcing the review stated that it was supported by the Institute for Scientific Information on Coffee, whose members are six major European coffee companies.

§Risks and limitations

The umbrella review found that, outside pregnancy, coffee seems generally safe at usual intakes. High consumption in pregnancy was associated with low birth weight, preterm birth, and pregnancy loss, and coffee drinking was associated with fracture risk in women but not in men.² Cohort exposure measures are coarse: a "cup" varies in volume, strength, and preparation, and the largest studies often record intake once and follow participants for a decade or more.

§Outlook

The umbrella review's authors argued that coffee could be tested as an intervention, outside pregnancy, without significant risk of harm.² A trial with mortality as its endpoint would still be very large and long, hard to blind, and without a commercial sponsor able to recover its cost, the same obstacle that has stalled the TAME trial. Validated Aging biomarkers could shorten such a trial, but no Epigenetic clocks is yet accepted as a surrogate for survival. If larger genetic studies continue to find nothing, the simplest reading of the mortality association would be that coffee drinkers are healthier, not that coffee made them so. Unlike exercise, coffee has no randomized trial showing a functional benefit in older people to fall back on.

§See also

• Hallmarks of aging
• Healthspan
• Exercise as a geroprotector
• Sleep and longevity
• Dietary supplements
• Nootropics
• Metformin and the TAME trial
• Blue Zones

§References